Australian Institute for Bioengineering and Nanotechnology
Research - Brisbane, Queensland, Australia
Australian Institute for Bioengineering and Nanotechnology Employees
Australian Institute for Bioengineering and Nanotechnology Details
The AIBN is an integrated multi-disciplinary research institute bringing together researchers in the areas of bioengineering and nanotechnology. It is home to research groups working at the interface of the biological, chemical and physical sciences, and its applications in human health and environmental issues.Notable work performed by the institute includes the needleless Nanopatch vaccine delivery device that is ready to begin human trials; local production of an experimental antibody for the treatment of the Hendra virus; and biofuel research.AIBN's research efforts are focused in the areas of:1. Nanotechnology-based imaging and drug delivery for therapeutic products;2. Regenerative medicine: biology, stem cells and novel scaffolds;3. Novel protein expression utilising metabolomics and systems biotechnology;4. Nanotechnology for energy and environmental applications.The Institute has set up an Industrial Affiliates Program to tackle technological issues confronting the industry.AIBN has established products and created companies based on the technology developed within it. Four start-up companies currently operate largely or exclusively out of AIBN. Institute researchers founded three companies to develop AIBN technology – Vaxxas Pty Ltd (vaccine delivery), TenasiTech Pty Ltd (bio-plastics), and Pepfactants Pty Ltd – while Acyte, founded by AIBN Director Professor Peter Gray, was brought to AIBN from The University of New South Wales.The start-up companies are distinct entities, with their own management structures, boards and finances. AIBN provides facilities, equipment and, through The University of Queensland's commercialisation company UniQuest, a level of specialist support, such as management of patents and commercial advice.
